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Abstract
Introduction Mortality of severe acute respiratory distress
syndrome in adults is still unacceptably high. Extracorporeal
membrane oxygenation (ECMO) could represent an important
treatment option, if complications were reduced by new
technical developments.
Methods Efficiency, side effects and outcome of treatment with
a new miniaturized device for veno-venous extracorporeal gas
transfer were analysed in 60 consecutive patients with life-
threatening respiratory failure.
Results A rapid increase of partial pressure of arterial oxygen/
fraction of inspired oxygen (PaO2/FiO2) from 64 (48 to 86)
mmHg to 120 (84 to 171) mmHg and a decrease of PaCO2
f r o m  6 3  ( 5 0  t o  8 0 )  m m H g  t o  3 3  ( 2 9  t o  3 9 )  m m H g  w e r e
observed after start of the extracorporeal support (P < 0.001).
Gas exchange capacity of the device averaged 155 (116 to
182) mL/min for oxygen and 210 (164 to 251) mL/min for
carbon dioxide. Ventilatory parameters were reduced to a highly
protective mode, allowing a fast reduction of tidal volume from
495 (401 to 570) mL to 336 (292 to 404) mL (P < 0.001) and
of peak inspiratory pressure from 36 (32 to 40) cmH2O to 31
(28 to 35) cmH2O (P  < 0.001). Transfusion requirements
averaged 0.8 (0.4 to 1.8) units of red blood cells per day. Sixty-
two percent of patients were weaned from the extracorporeal
system, and 45% survived to discharge.
Conclusions Veno-venous extracorporeal membrane
oxygenation with a new miniaturized device supports gas
transfer effectively, allows for highly protective ventilation and is
very reliable. Modern ECMO technology extends treatment
opportunities in severe lung failure.
Introduction
Despite relevant improvements in the treatment of acute respi-
ratory distress syndrome (ARDS) mortality remains high. The
estimated annual number of deaths due to acute lung injury
was calculated as 74,500 for the US in a population-based
study in 2005 [1]. Mortality in severe ARDS with a high lung-
injury score (>3.5) and a low oxygenation index is reported to
be considerably higher and may reach more than 80% [2,3].
An observational study in Europe found a mortality rate of
62.5% for ARDS with a PaO2/FiO2-ratio below 150 mmHg
[4].
Extracorporeal membrane oxygenation (ECMO) has been
advocated as rescue therapy in severe ARDS with presumed
ALI: acute lung injury; aPTT: activated partial thromboplastin time; ARDS: acute respiratory distress syndrome; BMI: body mass index; BW: body 
weight; CESAR: Conventional ventilation or ECMO for Severe Adult Respiratory Failure; DIC: disseminated intravascular coagulopathy; ECMO: extra-
corporeal membrane oxygenation; ELSO: Extracorporeal Life Support Organization; FFP: fresh frozen plasma; FiO2: fraction of inspired oxygen; LDH: 
lactic dehydrogenase; LIS: lung injury score; MAP: mean arterial pressure; MV: minute ventilation; PaCO2: partial pressure of arterial carbon dioxide; 
PaO2: partial pressure of arterial oxygen; PC: platelet concentrate; PEEP: positive end-exspiratory pressure; PIP: plateau inspiratory pressure; RBC: 
red blood cell concentrate; SOFA: sequential organ failure assessment; TV: tidal volume; VILI: ventilator induced lung injury.Critical Care    Vol 13 No 6    Müller et al.
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improved survival in specialized centres [5-7]. Historic ran-
domised clinical trials could not prove superiority of ECMO-
treatment compared to conventional treatment [8,9]. High
rates of thrombo-embolic complications and hemorrhagic
events had been reported, so that ECMO treatment gained
only limited acceptance in adults.
Recently, a new miniaturized system for long-term extracorpor-
eal gas exchange has been approved in Europe. The small size
of this device with reduced foreign surface combined with
heparin-coating, a plasma-resistant membrane and improved
pump technology decreases the need for systemic anticoagu-
lation. Encouraging results in the treatment of pediatric
patients [10] and adults with cardiogenic shock [11] have
been published. Hitherto, there have been no reports on the
use of this system in acute lung failure. We present our expe-
rience in a relevant sample of adult patients with severe ARDS,
analysing the efficiency of the device as well as reporting on
observed complications and patient outcome.
Material and methods
Study population
From April 2006 to December 2008, 60 patients with severe
lung failure were treated with the new device in a veno-venous
mode. The leading cause of lung failure was pneumonia; all
diagnoses are listed in Table 1. More than 70% of patients
were transferred from external hospitals. According to a pre-
defined algorithm, in all patients an attempt to improve oxygen-
ation with conventional ventilation was undertaken. This
included an effort to optimise positive end-exspiratory pres-
sure (PEEP); one recruitment manoeuvre was done in patients
with early ARDS. In patients, who were hemodynamically sta-
ble, prone positioning was attempted to optimize gas
exchange. Six patients were on high-frequency oscillatory ven-
tilation before extracorporeal support, all other patients were
ventilated in a pressure-controlled mode. If stabilisation efforts
were not successful after several hours and severe ARDS [12]
with a PaO2/FiO2 ratio of <85 mmHg and/or severe respira-
tory acidosis with a pH of <7.25 persisted, extracorporeal lung
support was considered. In 10 patients proving too instable
for transport, our mobile team implanted the portable veno-
venous ECMO in the referring hospital. Patient characteristics
before inclusion are specified in Table 2. Patients on a veno-
arterial ECMO were not included in this analysis.
Technique of extracorporeal support
The extracorporeal system consists of two venous cannulae, a
centrifugal pump and a membrane oxygenator (Figure 1). For
outflow commonly the right femoral vein was cannulated in
Seldinger technique with a long 21 to 23-Fr cannula (Sorin-
Group Deutschland-GmbH, Munich, Germany). For reinfusion
a short 15 to 17-Fr cannula (NovaLung-GmbH, Talheim, Ger-
many) was used, that was usually implanted in the right internal
jugular vein. Blood flow was generated by a centrifugal pump
(Rotaflow-Centrifugal Pump, Maquet-Cardiopulmonary-AG,
Hirrlingen, Germany) with an integrated battery for transport.
The membrane oxygenator (PLS-QuadroxD, Maquet-Cardiop-
ulmonary-AG) is made of polymethylpentene, which avoids
plasma-leakage and has a total gas exchange surface of 1.8
m2 with a very low inherent resistance. The filling volume of the
complete device is between 400 and 500 mL, depending on
the length of the tubing. The whole system is coated with
heparin, hence a pronounced systemic anticoagulation is
unnecessary and a partial thromboplastin time (aPTT) of 1.5
normal is sufficient. Usually 100 mg/day of acetylsalicylic acid
were given to inhibit platelet aggregation. Oxygen was used as
sweep-gas with a flow of 1 to 12 L/min. Blood gas analysis
was done with Radiometer-700 (Radiometer, Copenhagen,
Denmark).
The oxygen transfer capacity of the ECMO was calculated by
multiplying the difference of oxygen content pre and post
ECMO with the blood flow. The approximated carbon dioxide
content, calculated by the blood gas analyser with considera-
tion of the Henderson-Hasselbalch equation, plasma-PCO2
and pH, was used for calculation of carbon dioxide removal, as
CO2 measurement in exhaust-gas, the preferable method, was
not available.
Table 1
Diagnosis leading to ARDS and outcome
All Survival off ECMO Survival to Discharge
Total (No, %) 60 (100) 37 (62) 27 (45)
Pneumonia 25 16 14
Aspiration 11 6 3
Sepsis 15 7 3
Multiple Trauma 43 2
Other 55 5
Other = two cases of diffuse alveolar hemorrhage, one case each of fulminant Still's disease, near fatal asthma and combined pneumonia with 
pulmonary embolismAvailable online http://ccforum.com/content/13/6/R205
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Patient management on ECMO and weaning from 
extracorporeal support
After implementation of the ECMO, invasiveness of ventilation
was reduced to diminish further ventilator-induced lung injury
(VILI). Goals for oxygenation were a PaO2 of 75 mmHg and
PaCO2 was adjusted to achieve a normal pH level. Accord-
ingly, tidal volume (TV), minute ventilation (MV), inspiratory
pressure (PIP) and fraction of inspired oxygen (FiO2) were
decreased. Positive end-expiratory pressure (PEEP) was ini-
tially not reduced to avoid atelectasis due to small TV. A rec-
ommendation for substitution was given for a hemoglobin level
below 8 g/dl.
After successful treatment of the underlying disease and
improvement of lung function (FiO2 < 0.5, PEEP <10 cmH2O,
PIP <27 cmH2O), extracorporeal blood flow was stepwise
reduced to 1.5 L/min. Thereafter, gas flow was tapered and
finally shut off for 30 minutes. If blood gases remained stable,
the ECMO system was removed and decannulation with man-
ual compression was carried out.
Data collection and statistical analysis
Data were collected prospectively. Blood gas analysis, ventila-
tory parameters, hemodynamics and vasopressor therapy
were documented immediately before initiation of ECMO, after
two hours, thereafter once a day and for two days after ECMO
treatment.
Approval for this study was gained from the Ethics Committee
of the University of Regensburg. Obtainment of informed con-
sent was deemed by the Institutional Review Board not to be
required, as the device is approved for long-term therapy and
use was considered a rescue therapy in the majority of
patients.
Variables are reported as median and interquartile ranges, if
not told otherwise, after testing for normal distribution with the
Kolmogorov-Smirnov test. Nonparametric test procedures
were used for paired analysis (Wilcoxon signed-rank test) and
unpaired analysis (Mann-Whitney test). A P-value of less than
0.05 was considered statistically significant. For statistical
analysis, we used SPSS 15.0 (SPSS-Inc, Chicago, IL, USA).
Results
Study population
A total of 60 patients with severe respiratory insufficiency were
treated with the new miniaturized device, all but two fulfilling
the definition of ARDS [12]. The most common cause was
Table 2
Patient data and characteristics before extracorporeal lung support
All Patients Survivors Non-Survivors
Number 60 27 (45%) 33 (55%)
Age (Years) 53 (21 to 78) 49 (21 to 74) 54 (21 to 78) *
Female/Male Ratio 15/45 6/21 9/24
BMI (kg/m2) 29 (25 to 33) 27 (24 to 33) 29 (26 to 33)
Days on Ventilation 1.0 (1.0 to 4.8) 1.0 (0.9 to 2.0) 2.0 (1.0 to 7.0)
SOFA Score 14 (11 to 16) 11 (10 to 14) 15 (13 to 17) *
LIS Score 3.6 (3.3 to 3.8) 3.5 (3.3 to 3.8) 3.8 (3.3 to 3.8)
Acute Renal Failure 28 (47%) 6 (22%) 22 (67%) **
Norepinephrine (mcg/kg/min) 0.35 (0.15 to 0.84) 0.56 (0.15 to 0.86) 0.33 (0.16 to 0.81)
PaO2/FiO2 (mm Hg) 64 (48 to 86) 68 (53 to 92) 62 (48 to 86)
PaCO2 (mm Hg) 63 (50 to 80) 62 (52 to 89) 64 (47 to 74)
pH 7.20 (7.13 to 7.30) 7.18 (7.12 to 7.24) 7.24 (7.13 to 7.35)
Tidal Volume (mL) 495 (401 to 570) 489 (393 to 599) 500 (404 to 570)
TV/kg pred. BW (mL) 7.4 (6.1 to 8.6) 7.2 (6.1 to 8.9) 7.6 (6.1 to 8.5)
Minute Volume (mL/min) 13.1 (11.0 to 16.2) 13.1 (10.0 to 16.8) 13.5 (11.2 to 16.2)
PIP (cm H2O) 36 (32 to 40) 35 (31 to 39) 36 (33 to 40)
PEEP (cm H2O) 16 (13 to 20) 16 (13 to 20) 16 (14 to 20)
Data are presented as median (interquartile range) except for female/male ratio and acute renal failure. For age, the full range is given. * P < 0.05; 
** P < 0.001
BMI = body mass index, SOFA = sequential organ failure assessment, LIS = lung injury score, TV/kg pred. BW = tidal volume per kilogram 
predicted bodyweight, PIP = plateau inspiratory pressure, PEEP = positive end-exspiratory pressure.Critical Care    Vol 13 No 6    Müller et al.
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double-sided pneumonia, usually community acquired or due
to aspiration. Further triggers of ARDS were sepsis and multi-
ple trauma, all reasons of respiratory failure are presented in
Table 1. Thirteen patients had a platelet count of <80/nl
before inclusion, and 22 patients displayed signs of dissemi-
nated intravascular coagulopathy (DIC) with an aPTT of >60
sec. All but three patients depended on norepinephrine, and
47% presented with acute renal failure, defined as need for
replacement therapy. Further patient characteristics before
cannulation are summarized in Table 2.
Thirty-seven patients (62%) were successfully weaned from
ECMO. Of these, 10 patients died during their further course
in the intensive care unit; 30-day survival was 52%, and 27
patients (45%) survived to discharge. A significant difference
between non-survivors and survivors was demonstrated for
age, sequential organ failure assessment (SOFA) score and
acute renal failure.
Gas exchange, hemodynamics and respiratory 
parameters
Within two hours a fast rise in oxygenation occurred. PaO2/
FiO2 increased from 64 (48 to 86) mmHg to 120 (84 to 171)
mmHg (P < 0.001). In parallel, PaCO2 decreased from 63 (50
to 80) mmHg to 33 (29 to 39) mmHg (P < 0.001) (Figure 2a
and 2b). Respiratory acidosis was controlled within two hours.
Additional data for the following days on and after ECMO are
summarized in Table 3. Simultaneously mean arterial pressure
(MAP) increased from 67 (59 to 76) mmHg to 77 (69 to 86)
mmHg (P < 0.001), despite a notable reduction in norepine-
phrine dose (P < 0.001).
Oxygen transfer by the device was calculated with 155 (116
to 182) mL/min after two hours and remained stable until the
end of treatment (Table 3). The maximum measured value
equalled a transfer of 284 mL oxygen/min. Approximated car-
bon dioxide elimination was calculated with 210 (164 to 251)
mL/min two hours after implantation. Blood flow through the
device averaged 2.7 (2.5 to 3.0) L/min at two hours with a
mean rotational speed of 2500 r/min. Gas flow was started
with 4 L/min and was set to 6 (4 to 8) L/min after adjustment
for pH-level at two hours. Median length of treatment on
Figure 1
Miniaturized device for extracorporeal lung support Miniaturized device for extracorporeal lung support. The device 
was obtained from Maquet Cardiopulmonary AG, Hirrlingen, Germany.
Figure 2
Gas exchange parameters before and after initiation of extracorporeal  support Gas exchange parameters before and after initiation of extracor-
poreal support. Figure 2a represents PaO2/FiO2, Figure 2b represents 
PaCO2 ** P < 0.001.Available online http://ccforum.com/content/13/6/R205
Page 5 of 10
(page number not for citation purposes)
ECMO was 9 (5 to 13) days. There was a trend towards longer
treatment in non-survivors, the longest application lasting 33
days.
Mechanical ventilation before inclusion was highly invasive
(Table 2). One day after initiation of the ECMO all parameters
could be significantly reduced towards a more protective ven-
tilation with an FiO2 of 0.6 (0.55 to 0.70), a PIP of 30 (27 to
34) cmH2O and a TV of 4.8 (3.6 to 6.1) mL/kg of predicted
BW (Table 4). After termination of ECMO, MV and TV had to
be increased as expected.
Complications and side effects
Laboratory values before, during and after extracorporeal
assist are presented in Table 5. Hemoglobin levels and platelet
counts dropped during treatment with ECMO (P < 0.001). For
every patient 9 (3 to15) red blood cell (RBC) concentrates, 4
(0 to 14) units of fresh frozen plasma (FFP) and 0 (0 to 4)
platelet concentrates were transfused during the period on
Table 3
Gas exchange and hemodynamic parameters before, during and after extracorporeal support
Pre ECMO 2 Hours Day 1 Day 2 End of ECMO, 
Survivors
End of ECMO,
Non-Survivors
Day 1 after 
ECMO
PaO2/FiO2 (mm 
Hg)
64
(48 to 86)
120 **
(84 to 171)
125 **
(108 to 160)
148 **
(108 to 191)
218 **
(181 to 290)
174 **
(136 to 193)
194 **
(144 to 245)
PaCO2 (mm Hg) 63
(50 to 80)
33 **
(29 to 39)
36 **
(31 to 41)
37 **
(32 to 40)
40 **
(35 to 46)
35 **
(27 to 42)
44 **
(36 to 49)
pH 7.20
(7.13 to 7.30)
7.42 **
(7.34 to 7.49)
7.43 **
(7.37 to 7.49)
7.44 **
(7.38 to 7.50)
7.43 **
(7.39 to 7.45)
7.31 *
(7.21 to 7.41)
7.41 **
(7.32 to 7.47)
MAP (mm Hg) 67
(59 to 76)
77 **
(69 to 86)
72 *
(66 to 79)
76 **
(70 to 87)
80 *
(71 to 90)
65
(55 to 72)
80 *
(70 to 86)
Norepinephrine 
(μg/kg/min)
0.35
(0.15 to 0.84)
0.28 **
(0.12 to 0.55)
0.15 **
(0.04 to 0.29)
0.10 **
(0.04 to 0.24)
0.00 **
(0.00 to 0.05)
0.27
(0.06 to 0.67)
0.00 **
(0.00 to 0.07)
O2 transfer ECMO
(mL/min)
155
(116 to 182)
157
(128 to 178)
160
(129 to 195)
80 **
(74 to 93)
111
(99 to 160)
CO2 transfer 
ECMO
(mL/min)
210
(164 to 251)
193 *
(164 to 218)
195
(158 to 232)
116 **
(96 to 150)
170
(136 to 225)
ECMO flow 
(L/min)
2.7
(2.5 to 3.0)
2.8
(2.5 to 3.1)
2.9 *
(2.5 to 3.2)
1.6 **
(1.5 to 1.8)
2.0 *
(1.8 to 3.0)
The measurement at the end of extracorporeal support is separated in survivors and non-survivors (to discharge).
Data are presented as median (interquartile range). * P < 0.05, ** P < 0.001 to first measurement. (ECMO = extracorporeal membrane 
oxygenation, MAP = mean arterial pressure)
Table 4
Respiratory parameters before, during and after extracorporeal support
Pre ECMO 2 Hours Day 1 Day 2 End of ECMO, 
Survivors
End of ECMO, 
Non-Survivors
Day 1 after 
ECMO
FiO2 1.0
(1.0 to 1.0)
0.80 **
(0.60 to 0.90)
0.60 **
(0.55 to 0.70)
0.50 **
(0.45 to 0.68)
0.40 **
(0.35 to 0.45)
0.50 **
(0.45 to 0.60)
0.45 **
(0.40 to 0.50)
Minute Ventilation 
(L/min)
13.1
(11.0 to 16.2)
7.6 **
(4.9 to 10.0)
7.0 **
(5.0 to 8.5)
6.5 **
(4.7 to 8.5)
7.6 **
(6.2 to 11.3)
7.9 **
(5.7 to 9.8)
11.0
(10.0 to 14.0)
Tidal Volume (mL) 495
(401 to 570)
336 **
(292 to 404)
308 **
(254 to 400)
327 **
(229 to 415)
431
(322 to 509)
400
(293 to 497)
526
(443 to 640)
Tidal Volume per 
kg pred. BW 
(ml/kg)
7.4
(6.1 to 8.6)
5.1 **
(4.4 to 5.9)
4.8 **
(3.6 to 6.1)
4.8 **
(3.4 to 6.1)
6.6
(4.6 to 7.7)
5.9
(4.5 to 8.1)
7.4
(6.6 to 9.4)
Peak Inspiratory 
pressure 
(cm H2O)
36
(32 to 40)
31 **
(28 to 35)
30 **
(27 to 34)
29 **
(26 to 32)
23 **
(19 to 26)
28 **
(24 to 32)
26 **
(22 to 27)
The measurement at the end of extracorporeal support is separated in survivors and non-survivors (to discharge).
Data are presented as median (interquartile range). ** P < 0.001 to pre ECMO. (ECMO = extracorporeal membrane oxygenation, BW = body 
weight)Critical Care    Vol 13 No 6    Müller et al.
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ECMO. The number of substituted blood products per day is
displayed in Table 6 with a higher need for transfusion in non-
survivors.
Complications during ECMO treatment are summarized in
Table 6. Technical problems that could not be controlled were
not observed. The pump head was changed due to a small
thrombus in one patient with heparin-induced thrombocytope-
nia. A change of the oxygenator was necessary in 10 patients,
which results in an average oxygenator time of eight days. An
accidental dislocation of the backflow cannula happened two
times, leading to rapid asystole due to hypoxia in one case.
Two patients needed resuscitation during implantation; both
were stabilized. One patient was converted to veno-arterial
ECMO for cardiac reasons.
The most common cause for death was intractable septic
shock and multiple organ failure (81%), generally despite suf-
ficient oxygenation with ECMO, as can be seen in Table 3 (end
of ECMO, non-survivors). Three patients died as a result of
cardiac failure, and two patients died due to pulmonary and
cerebral hemorrhage, the latter 32 days after weaning.
Discussion
The current study presents for the first time the use of a new
miniaturized system for extracorporeal membrane oxygenation
in a large adult study population with severe ARDS. Crucial
Table 5
Laboratory variables before, during and after extracorporeal support
Pre ECMO Day 1 Day 2 End of ECMO, Survivors End of ECMO, 
Non-Survivors
Day 1 after ECMO
Hemoglobin (g/dL) 10.4
(9.0 to 12.3)
9.5 **
(8.8 to10.4)
9.2 **
(8.4 to 9.6)
8.7 **
(8.3 to 9.4)
8.7 *
(7.7 to 9.3)
8.8 **
(8.3 to 9.9)
Platelets (/nL) 158
(82 to 266)
115 **
(60 to 160)
85 **
(40 to 149)
113 **
(76 to 146)
46 **
(22 to 86)
110 **
(66 to 154)
aPTT (sec) 53
(40 to 69)
58
(46 to 74)
53
(45 to 59)
47
(41 to 59)
62
(44 to 118)
42
(34 to 51)
LDH (U/L) 400
(289 to 684)
462
(293 to 885)
550 *
(323 to 941)
422
(276 to 550)
903 *
(442 to 9712)
444
(346 to 515)
Lactic Acid (mg/dl) 50
(19 to 80)
37
(19 to 73)
25 *
(17 to 43)
12 **
(10 to 18)
86
(15 to 161)
11 **
(7 to 4)
The measurement at the end of extracorporeal support is separated in survivors and non-survivors (to discharge).
Data are presented as median (interquartile range). * P < 0.05, ** P < 0.001 to pre ECMO. ECMO = extracorporeal membrane oxygenation, LDH 
= lactic dehydrogenase, aPTT = activated partial thromboplastin time.
Table 6
Frequency of complications during treatment with ECMO
Complications All Patients Survivors Non-Survivors
Thrombosis of Oxygenator 10 4 6
Failure of Pump Head 110
Cannulation Site Bleeding 220
Surgical Site Bleeding 11 4 7
Pulmonary Hemorrhage 312
Diffuse Bleeding 514
Femoral Vein Thrombosis 532
Transfusion Requirements
RBC/Day on ECMO 0.8 (0.4 to 1.8) 0.6 (0.3 to 1.8) 1.0 (0.7 to 2.1) *
FFP/Day on ECMO 0.5 (0.0 to 2.6) 0.0 (0.0 to 1.5) 1.1 (0.1 to 3.1)*
PC/Day on ECMO 0.0 (0.0 to 0.7) 0.0 (0.0 to 0.6) 0.1 (0.0 to 0.9)
Data are presented as numbers or median (interquartile range). * P < 0.05.
(RBC = red blood cell concentrate, ECMO = extracorporeal membrane oxygenation, FFP = fresh frozen plasma, PC = platelet concentrate)Available online http://ccforum.com/content/13/6/R205
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technical innovations, easy application and a limited number of
side effects support its employment as a highly effective
method to secure vital gas exchange and to reduce further VILI
also in patients with an increased risk of hemorrhage.
Lately, a meta-analysis suggested that mortality from ARDS
may not have decreased since 1994 [13]. Hence, the authors
emphasized the need for future effective therapeutic interven-
tions. ECMO with improved technical equipment may prove to
be a valuable option. Its first successful application in a trauma
patient was published in 1972 [14]. Despite disappointing
outcomes in early trials [8,9], major improvements have been
achieved in the following years [5-7,15-18]. Recently a ran-
domised multicentre trial has been published, which found a
significantly improved survival without severe disability in the
ECMO group [19].
The current study population had a weaning rate from ECMO
of 62% and a survival rate of 45%. The median age of 53 years
of our study population was considerably higher compared to
all former trials including the CESAR trial (Table 7). Age is
known to be a risk factor for mortality [20,21]. Most of our
patients were in septic shock and presented with a median
SOFA-Score of 14 predicting a high mortality [22]; thrombo-
cytopenia or DIC, traditionally exclusion criteria for ECMO,
were no contraindication for inclusion. Therefore, in compari-
son to earlier studies our results appear acceptable in a pop-
ulation with a low probability for survival. Selecting the age
group between 20 and 40 years (n = 14), presenting with a
PaO2/FiO2 of 63 mmHg, a LIS of 3.75 and a SOFA-score of
12.5, the survival rate in our study was 79%. In a retrospective
analysis, older age, acute renal failure before initiation of
ECMO therapy and a higher SOFA-score were predictors of a
higher mortality (Table 2). Extrapulmonary sepsis and aspira-
tion pneumonia held a lower survival rate than double-sided
pneumonia of bacterial or viral origin (Table 1).
Initiation of ECMO led to a rapid and sustained improvement
of blood gases and a correction of respiratory acidosis with
hemodynamic stabilisation The median calculated oxygen
transfer of the device amounted to 155 mL/min, which is about
half of the average total oxygen consumption, as we have
shown previously in a comparable group of patients with
ARDS [23]. The oxygen transfer rate depends on hemoglobin,
venous saturation and blood flow. As the flow rate is limited by
the cannula size, many authors favour a high hemoglobin con-
tent to increase oxygen transport capacity [5,6,17]. However,
several trials have shown in the past that a liberal RBC substi-
tution may increase mortality in intensive care [24,25]. Taking
both positions into account we had decided to aim at a more
restrictive transfusion policy with a recommended hemoglobin
level of >8 g/dl. Being aware that this reduces the oxygen
transfer capacity of the device we assent that the optimal
hemoglobin level for extracorporeal support is still a matter of
discussion.
Table 7
Studies and registries about ECMO in adult patients with severe ARDS
Study
(Year)
Number Age
(Years)
PaO2/FiO2 (mm Hg) LIS Survival (%)
CESAR Trial
(2009) [19].
90/68 treated 39.9 +/- 13 75.9 +/- 29.5 3.5 +/- 0.6 63
ELSO Registry
(2009) [20].
1473 34
(16.0 to 84.2)
57 (46,75) nr 50
Beiderlinden et al
(2006) [18].
32 42.2 +/- 13 63 +/- 28 3.8 +/- 0.3 53
Hemmila et al
(2004) [7].
255 38.4 55 +/- 16 nr 52
Mols et al
(2000) [16].
62 35 +/- 11 96 +/- 51 3.2 +/- 0.4 55
Linden et al
(2000) [17].
17 33.8 46 3.5 76
Peek et al
(1997) [6].
50 30.1 65 +/- 37 3.4 63
Lewandowski et al
(1997) [5].
49 31.5 +/- 14 67 +/- 28 3.4 +/- 0.3 55
Morris et al
(1994) [9].
21 33 +/- 3.1 62.6 +/- 4.2 nr 33
Gattinoni et al
(1986) [15].
43 26 (2 to 56) 62 - 72 nr 49
ELSO = Extracorporeal Life Support Organization, LIS = lung injury score, nr = not reported.Critical Care    Vol 13 No 6    Müller et al.
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Carbon dioxide elimination of the new device exceeds the rate
of oxygen transfer. Gattinoni proved more than 20 years ago,
that carbon dioxide removal is possible with an extracorporeal
flow of <30% of cardiac output [15]. Extracorporeal gas trans-
fer allows a reduction of aggressive ventilatory patterns, which
is essential to avoid further VILI. In the current study, FiO2, PIP
and MV were reduced significantly after commencement of
ECMO. TV/kg of predicted BW was decreased to 4.8 mL at
Day 1, a range that can be considered highly protective [26].
In contrast to earlier studies [6,7,15,16], in the present study
PEEP initially was not reduced to avoid progressive atelectasis
and to preserve function of the native lung. Consequently, we
did not have to provide total oxygen requirements and were
able to run the ECMO in a less injurious mode.
ECMO is a procedure with potentially serious complications.
With the new device, we did not encounter mechanical com-
plications that were life threatening. In particular, rupture of the
tubing or leakage of the oxygenator did not occur. Oxygenator
failure was exclusively a result of slowly progressing throm-
botic occlusion. As the system is coated with heparin, we
aimed at an aPTT of about 1.5 normal. This decreased the rate
of blood transfusions, which had been considerably higher in
earlier studies [6-9], despite the fact that the current study
included patients with multiple trauma, thrombocytopenia and
DIC. In several patients with manifest bleeding, systemic anti-
coagulation was temporarily interrupted up to several days
without clotting of the device. Adding all blood components
together, a total of 1,777 units were given. Butch reported a
transfusion need of more than 15,000 units of blood compo-
nents in 74 adult patients treated with ECMO [27]. Ang found
an average daily need of two units of RBC, three units of plate-
lets and 0.6 units of FFP [28].
Peek et al recommended the transfer of adult patients with
severe respiratory failure to a centre with an ECMO-based
management protocol [19]. However, transport on ECMO had
not been possible in the CESAR trial and five patients in the
ECMO group died before transport or in transit. With the min-
iaturized device of the present study, interhospital transport
has been carried out in 10 of our patients and others without
complications [29]. Costs for the device including cannulation
are estimated to be about 3,000 €. Labour resources are not
high, amounting in our institution to a circuit check twice daily
to document gas exchange and pressure drop across the
oxygenator.
The present study has limitations. It is a single centre experi-
ence without a randomised control group. Comparison of mor-
tality with a historical control group is biased, as general
treatment of ARDS has changed substantially in the last dec-
ade. In the past mortality rates of >80% have been reported in
severe ARDS [2]. A prospective randomised trial on ECMO is
difficult to conduct, as many centres would consider it unethi-
cal to withhold a potentially life-saving treatment for a control
group. However, with a here documented low rate of compli-
cations, a randomised prospective multicenter trial with the
new device should be taken into account. This could include
patients with early ARDS due to severe community-acquired
pneumonia with a PaO2/FiO2 ratio <100 mmHg on optimal
protective ventilation despite a trial of prone positioning. Ultra-
protective ventilation on ECMO would be compared to a con-
trol group on conventional protective ventilation; in life-threat-
ening hypoxemia (PaO2/FiO2 ratio <50 mmHg) cross-over to
the ECMO group would be allowed. Several questions remain
unanswered. As mentioned before, the ideal hemoglobin-con-
tent on ECMO-treatment is currently not known. As ECMO
can activate inflammation and coagulation cascades, a contin-
uing effort to optimise biocompatibility is desirable.
Conclusions
The current miniaturized system enables extracorporeal lung
support with more than 50% of total gas exchange. Improved
oxygenator, tubing and centrifugal pump allow less systemic
anticoagulation compared to earlier trials. The rate of hemor-
rhagic complications is markedly reduced, which makes its
implementation possible in patients with a risk of bleeding and
older age, which had been traditionally contraindications for
ECMO therapy. A fast and sustained rise in PaO2/FiO2 as well
as a rapid decrease in PaCO2  and normalization of pH
resulted in a clearly more protective ventilation. Therefore, a
reduction of VILI can be assumed and time was gained for lung
healing. Labour resources are low, and serious technical com-
plications were not encountered. Miniaturization and improved
biocompatibility of ECMO will extend the indication for its
employment from a rescue therapy at present to an effective
therapeutic intervention to avoid injurious ventilator settings in
ARDS in the future.
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